Skip to main content

Table 4 Baseline demographic characteristics of 11 participants with TAMs mutation

From: HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China

Sample code

Gender

Age

VL

CD4 counts

Occupation

WB date

ART regimen

Duration of ART

Transmission route

Genotype

NRTIs

NNRTIs

HB0041

Male

29

17,600

181

Worker

2010-7-9

3TC + d4T + NVP

26

Heterosexual

CRF01_AE

D67N, K70R, M184V, K219Q

A98G, K101E, G190A

HB0455

Male

39

51,200

85

Farmer

2010-1-22

3TC + AZT + EFV

34

Heterosexual

B

M41L, D67N, K70R, L74I, M184V, T215F, K219Q

K101E, V106I, V179E, G190S

HB0549

Female

43

50,800

170

Farmer

2011-4-8

3TC + AZT + NVP

20

Heterosexual

CRF01_AE

D67N, T69N, K70R, M184V, T215F, K219E

K103N, Y181C

HB0595

Male

41

195,000

7

Liberal

professions

2009-1-9

3TC + AZT + NVP

15

Homosexual

CRF01_AE

D67N, K70R, M184V, T215F, K219E

Y188L

HB0711

Male

31

47,800

175

Jobless

2009-7-20

3TC + AZT + NVP

27

Heterosexual

CRF01_AE

D67N, T69N, K70R, V75M, M184V, T215I, K219Q

Y181C, H221Y

HB0829

Male

49

6360

187

Jobless

2007-5-31

3TC + AZT + NVP

32

Heterosexual

B

D67N, K70R, M184V, K219Q

G190A

HB0869

Male

36

26,500

15

Farmer

2010-6-28

3TC + AZT + NVP

33

Heterosexual

CRF01_AE

D67N, K70R, M184V, K219E

V90I, Y188W, F227L

HB1157

Male

50

10,600

184

Farmer

2003-7-16

3TC + AZT + NVP

10

Heterosexual

B

D67N, K70R, M184V, K219E

V90I, K103N, K238T

HB1160

Female

45

7030

9

Farmer

2003-4-1

3TC + TDF + LPV

133

Heterosexual

B

D67N, K70R, M184V, K219E

V90I, K103N, K238T

HB1161

Female

15

1580

136

Farmer

2004-2-19

3TC + AZT + NVP

80

Mother-to-child

B

D67N, K70R, M184V, K219E

V90I, K103N, K238T

HB1225

Female

71

46,400

59

Farmer

2001-12-14

3TC + d4T + NVP

84

Heterosexual

B

M41L, L74V, M184V, L210W, T215Y

K103N, V108I, Y181C, H221Y

  1. WB western blot, VL viral load, NRTIs nucleoside reverse transcriptase inhibitors, NNRTIs non-nucleoside reverse transcriptase inhibitors